Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes
Sign Up to like & getrecommendations! Published in 2024 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2023-008724
Abstract: Background Patients with paraneoplastic syndromes (PNS) are excluded from clinical trials involving immune checkpoint inhibitors (ICIs) due to safety concerns. Moreover, real-world data on efficacy and safety is scarce. Methods In this retrospective study, data… read more here.
Keywords: without pns; cohort; patients pns; occurred patients ... See more keywords